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SULTS: Compared to patients treated with ziprasidone,
data seem to suggest that olanzapine patients had a
higher response rate, a higher incidence of weight gain,
and a lower incidence of QTc prolongation. Total medi-
cal cost was higher for ziprasidone patients when the
medication cost of ziprasidone was assumed to be more
than half the price than that of olanzapine. The olanza-
pine group’s costs were more sensitive to changes in drug
costs, whereas the ziprasidone group’s costs were more
sensitive to the response rate of the medication used for
those patients not responsive to ziprasidone. CONCLU-
SIONS: Compared to ziprasidone patients, olanzapine
patients may have a higher response rate, a higher inci-
dence of weight gain, and a lower incidence of QTc pro-
longation, with lower total costs as long as ziprasidone is
more than half the price of olanzapine.
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OBJECTIVES: We report on trends in medication adher-
ence for patients who received conventional and atypical
antipsychotics under routine outpatient care during a
9-month period in 1998–9. METHODS: Refill records
were analyzed for over 25,000 patients at a national re-
tail pharmacy chain. Persistence was defined as a pa-
tient’s possession of medication at 30 day intervals from
a patient’s initial prescription. Persistence was taken as a
proxy for medication adherence. RESULTS: The percent-
age of patients adhering to therapy at nine months was
44.4% for atypical agents; 47.6% for conventional
agents; and 71.1% for clozapine. CONCLUSIONS: Im-
proved clozapine adherence was associated with a closely
supervised medication administration process that en-
sured patient tracking and frequent and sustained pa-
tient-provider contact. Atypical agents, with their im-
proved side-effect profile relative to conventional agents,
were not associated with better adherence. These results
suggest that improved side-effect profiles alone may not
insure higher levels of medication adherence and that im-
proved medication administration processes may facili-
tate higher levels of outpatient medication adherence for
patients with major mental illness.
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OBJECTIVE: Comparative cost-effectiveness was as-
sessed in an open-label, randomized trial (QUEST) that
compared the efficacy and safety of quetiapine with ris-
peridone in a outpatient population with schizophrenia
or other psychotic disorders. METHOD: Based on the
overall Positive And Negative Syndrome Scale (PANSS)
scores, patients in QUEST were categorized into one of
three health states—mild (PANSS 74.5), moderate
(PANSS 74.5 and 106.5), or severe (PANSS score
106.5)—at baseline and at 2 months and 4 months.
Utilities and expected utilities from baseline were calcu-
lated. RESULTS: At baseline, 297 (54.0%), 206 (37.5%),
and 47 (8.5%) quetiapine patients, had mild, moderate
or severe symptoms compared to 102 (59.0%), 55
(31.8%), and 16 (9.2%) in the risperidone group. For pa-
tients in the mild or moderate states at baseline, improve-
ments were seen in both treatment groups. For severe pa-
tients, more quetiapine patients improved: 21.2% versus
7.7% in the mild state and 60.6% versus 30.8% in the
moderate state (p  0.020) at 2 months and 46.9% ver-
sus 0.0% in the mild state and 40.6% versus 62.5% in
the moderate state (p  0.023) at 4 months. Overall,
when weighted by utilities, quetiapine treated patients at-
tained greater gains in health state utilities at each follow-
up visit for the mild (0.61  0.069), moderate (0.36 
0.073) and severe (0.29  0.071) states. At 2-months,
quetiapine patients enjoyed a gain of 0.239 from their
baseline level compared to 0.175 for the risperidone
group. At 4-months, the gains were 0.329 versus 0.184
for the quetiapine and risperidone groups (p  0.05). Av-
erage daily doses were 253.9mg quetiapine and 4.4mg
risperidone, yielding average daily costs to US consumers
of $6.38 and $7.85. At average retail costs to consumers
in the US, quetiapine reduces costs by $1.47/day or
$536.55 annually. CONCLUSION: Patients with schizo-
phrenia or other psychotic disorders, treatment with que-
tiapine resulted in significant effectiveness and cost sav-
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CONTEXT: So-called chronic depression, a limiting fac-
tor in terms of social reinsertion, must be diagnosed to
enable its management and to prevent a decline towards
a profound, desocialised state. OBJECTIVE: To deter-
mine the incidence of depression in populations of the
homeless, who are users of the Samu Social de Paris—
Paris Social Emergencies Unit—(SSP). METHOD: Once
an individual had been assessed and a response found to
his or her need, it was suggested that patients calling the
SSP free-phone number should agree to complete the
CES-D questionnaire. Developed in the US by Randloff
(1977), this questionnaire enables the detection of de-
pressive symptoms in a given population. Its use over the
